New
Lumia phones fail to impress investors
Yesterday, Nokia Corporation
(ADR)(NYSE:NOK) unveiled two new smartphones, Lumia 920 and Lumia 820. The
former has a tall display and uses PureView camera technology and has 32
gigabytes of storage. While this is a high end phone, the Lumia 820 caters to
the mid-end and is priced lower.
The phone maker is attempting to regain
its foothold in the phone market where competitors like Apple with the iPhone
and Google with its Android-based phones are doing better. But investors who were
probably expecting more exciting features, were clearly not impressed. In fact,
the stock tanked 16 percent to $2.36. The volumes traded were also four times
the daily average.
Find
Out How Should Investors Trade NOK Now
The
Finnish Company has not revealed any information on the price of the phone or
the date of its availability in the markets.
Orexigen
advances deadline for enrollment of patients
In the light of enrollment happening at
a faster than expected rate, Orexigen Therapeutics, Inc.(NASDAQ:OREX) has
modified the deadline for patient enrollment in its cardiovascular outcomes
clinical trial associated with the weight loss pill Contrave. As of August 31,
4500 patients had registered for the trial. The company now says that they plan
to stop accepting new enrollments in the fourth quarter of 2012. It had earlier
expected to complete the process only by the first quarter of next year.
Last year, Orexigen had stopped working
on Contrave, as regulators had wanted additional tests to be done. But this
year the Food and Drug Administration has said that it would approve the drug
provided certain criteria are met. This led to the company resuming work
related to drug development.
Will
OREX Continue To Move Higher? If Yes, How Far It can Go? Find Out Here
The advancement of the deadline will
mean that certain expenses related to the study will move from 2013 to 2012,
but does not change the company’s guidance in any way.
The Orexigen stock responded positively.
Shares of OREX opened higher by 11.20% to $5.46 after soaring 6.70% in
yesterday’s session.
No comments:
Post a Comment